未登录

K

Kaisa Huhtinen

University of Turku

H指数:30

被引数:2,921

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CA-125 glycovariant assays enhance diagnostic sensitivity in the detection of epithelial ovarian cancer

CA-125糖变体检测方法在检测上皮性卵巢癌方面提高了诊断敏感性。

CLINICAL CHEMISTRY AND LABORATORY MEDICINE

IF3.7

2025-09-010

OA

MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer

SCIENTIFIC REPORTS

IF3.9

2025-01-250

OAAI

Deciphering cancer genomes with GenomeSpy: a grammar-based visualization toolkit

IF3.9

2024-08-050

OAAI

PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures

IF7.7

2024-05-012

OAAI

Application of high-grade serous ovarian cancer organoids in functional precision medicine

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Establishment and analysis of patient-derived high-grade serous ovarian cancer organoids for disease modeling and drug testing

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Mutational and copy number-based ctDNA profiles mirror high-grade serous cancer tumors and enable detection of genetic changes appearing at recurrence

CANCER RESEARCH

IF16.6

2024-03-040

PRE

Stable subclones and acquired genomic events present after treatment of HGSC

CANCER RESEARCH

IF16.6

2024-03-040

PRE

Characterizing DNA methylation patterns driving chemotherapy resistance in ovarian high-grade serous carcinoma

CANCER RESEARCH

IF16.6

2024-03-040

PRE

Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma

CANCER RESEARCH

IF16.6

2024-03-040

PRE

Screening of drug candidates to repurpose for high-grade serous ovarian cancer treatment

CANCER RESEARCH

IF16.6

2024-03-040

PRE

Locus-specific LINE-1 expression in clinical ovarian cancer specimens at the single-cell level

SCIENTIFIC REPORTS

IF3.9

2024-02-210

OAAI

Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma

IF3.4

2024-02-051

OAAI

Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2023-12-011

OAAI

Multi-omics analysis of chemo-refractory high-grade serous carcinoma patients: Insights from the DECIDER study

ANNALS OF ONCOLOGY

IF65.4

2023-10-011

PRE

A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids

DEVELOPMENTAL CELL

IF8.7

2023-06-0128

OAAI

Senkowski, Wojciech; Gall-Mas, Laura; Falco, Matias Marin; Li, Yilin; Lavikka, Kari; Kriegbaum, Mette C.; Oikkonen, Jaana; Bulanova, Daria; Pietras, Elin J.; Vossgrone, Karolin; Chen, Yan-Jun; Erkan, Erdogan Pekcan; Dai, Jun; Lundgren, Anastasia; Hog, Mia Kristine Gronning; Larsen, Ida Marie; Lamminen, Tarja; Kaipio, Katja; Huvila, Jutta; Virtanen, Anni; Engelholm, Lars; Christiansen, Pernille; Santoni-Rugiu, Eric; Huhtinen, Kaisa; Carpen, Olli; Hynninen, Johanna; Hautaniemi, Sampsa; Vaharautio, Anna; Wennerberg, Krister

Characterizing dynamic landscape of DNA methylation in ovarian high-grade serous carcinoma

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Multi-omics characterization of chemo-refractory HGSC patients

CANCER RESEARCH

IF16.6

2023-04-040

PRE

A platform utilizing high-grade serous ovarian cancer organoids for prospective patient stratification in functional precision medicine

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

CLINICAL CANCER RESEARCH

IF10.2

2023-02-2010

OAAI